Two more articles, first one is an extreme brain recovery case -LINK
Other nutrients to consider, I would add lithium, uridine, and low inflammation/sugar diet to the mix - LINK
Edited by Gal220, 06 August 2021 - 10:16 PM.
Posted 07 August 2021 - 07:23 AM
Article on the motivation for the EGCG trial - LINK
Recent double-blind, placebo-controlled clinical trials, reported up to 75% reduction in the risk of respiratory infection by healthcare workers during an outbreak of H1N1 influenza, simultaneously enhancing systemic immunity by increasing proliferation of ϒδ T cells (28%) and production of IFN-γ (26%). In molecular docking studies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the causal agent of coronavirus disease 2019 outbreak also known as COVID-19) EGCG was identified as a candidate with very high potential for antiviral chemoprophylaxis of COVID-19.
Edited by Gal220, 07 August 2021 - 07:23 AM.
Posted 07 August 2021 - 04:23 PM
Ivermectin is the topic of discussion in the latest Coronapod Podcast. This is a Podcast from the journal Nature:
https://www.nature.c...86-021-02178-2
Posted 08 August 2021 - 12:14 AM
The compound, part of a class of molecules called salicylanilides, was designed in the laboratory of Professor Kim Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry and director of the Worm Institute for Research and Medicine at Scripps Research, in La Jolla, CA.
"It has been known for 10 or 15 years that salicylanilides work against certain viruses," Janda says. "However, they tend to be gut-restricted and can have toxicity issues."
Janda's compound overcomes both issues, in mouse and cell-based tests, acting as both an antiviral and an anti-inflammatory drug-like compound, with properties that auger well for its use in pill form.
Salicylanilides were first discovered in Germany in the 1950s and used to address worm infections in cattle. Versions including the drug niclosamide are used in animals and humans today to treat tapeworm. They have also been studied for anti-cancer and antimicrobial properties.
The modified salicylanilide compound that Janda created was one of about 60 that he built years ago for another project. When the SARS-CoV-2 virus became a global pandemic in early 2020, knowing that they may have antiviral properties, he started screening his old collection, first in cells with collaborators from Sorrento Therapeutics and The University of Texas Medical Branch, and later, after seeing promising results, working with Scripps Research immunologist John Teijaro, PhD, who conducted rodent studies.
One compound stood out. Dubbed simply "No. 11," it differs from the commercial tapeworm medicines in key ways, including its ability to pass beyond the gut and be absorbed into the bloodstream -- and without the worrisome toxicity.
"Niclosamide is basically digestive-track restricted, and that makes sense, because that's where parasites reside," Janda says. "For that reason, simple drug repurposing for a COVID treatment would be counterintuitive, as you want something that is readily bioavailable, yet does not possess the systemic toxicity that niclosamide has."
About 80 percent of salicylanilide 11 passed into the bloodstream, compared to about 10 percent of the antiparasitic drug niclosamide, which has recently entered clinical trials as a COVID-19 treatment, Janda says.
The experiments showed that of the many modified salicylanilides he had built in his laboratory, No. 11 affected pandemic coronavirus infections in two ways. First, it interfered with how the virus deposited its genetic material into infected cells, a process called endocytosis. Endocytosis requires the virus to form a lipid-based packet around viral genes. The packet enters the infected cell and dissolves, so the infected cell's protein-building machinery can read it and churn out new viral copies. No. 11 appears to prevent the packet's dissolution.
"The compound's antiviral mechanism is the key," Janda says. "It blocks the viral material from getting out of the endosome, and it just gets degraded. This process does not allow new viral particles to be made as readily."
Importantly, because it acts inside cells rather than on viral spikes, questions about whether it would work in new variants like Delta and Lambda aren't a concern, he adds.
"This mechanism is not dependent on the virus spike protein, so these new variants coming up aren't going to relegate us to finding new molecules as is the case with vaccines or antibodies," Janda says.
In addition, No. 11 helped quiet potentially toxic inflammation in the research animals, Janda says, which could be important for treating acute respiratory distress associated with life-threatening COVID infections. It reduced levels of interleukin 6, a signaling protein which is a key contributor of inflammation typically found in advanced stages of COVID-19.
Better medications against COVID-19 are urgently needed, as highly infectious new variants drive renewed surges of illness and death globally. But Janda says salicylanilide No. 11 was created long before the pandemic.
After fighting an unpleasant bacterial infection called Clostridioides difficile about 10 years ago,he saw a clear need for better treatment options. Multi-drug-resistant strains of C. difficile have become a major cause of drug-resistant diarrheal disease outbreaks in health care institutions globally, and among people using antibiotics. As director of the Worm Institute, which focused on parasitic infections, Janda was very familiar with salicylanilides, and knew of their antimicrobial properties. His laboratory created a "library" of modified salicylanilides several of which showed strong efficacy against C. difficile, and the collection was subsequently licensed by pharmaceutical firm Sorrento Therapeutics. Among them was salicylanilide 11.
"Salicylanilide 11 actually was placed on the back burner in my laboratory against C. difficile because it's not as gut-restricted as we would like it to be," Janda says. "But salicylanilide 11 has got a lot of really positive things going for it as a potential therapeutic for COVID."
Rest at link. Bolded and underlined emphasis is mine. Apparently this is previously licensed and should be cheap.
Posted 08 August 2021 - 01:31 PM
The compound, part of a class of molecules called salicylanilides, was designed in the laboratory of Professor Kim Janda, PhD, the Ely R. Callaway, Jr. Professor of Chemistry and director of the Worm Institute for Research and Medicine at Scripps Research, in La Jolla, CA.
"It has been known for 10 or 15 years that salicylanilides work against certain viruses," Janda says. "However, they tend to be gut-restricted and can have toxicity issues."
Janda's compound overcomes both issues, in mouse and cell-based tests, acting as both an antiviral and an anti-inflammatory drug-like compound, with properties that auger well for its use in pill form.
Salicylanilides were first discovered in Germany in the 1950s and used to address worm infections in cattle. Versions including the drug niclosamide are used in animals and humans today to treat tapeworm. They have also been studied for anti-cancer and antimicrobial properties.
The modified salicylanilide compound that Janda created was one of about 60 that he built years ago for another project. When the SARS-CoV-2 virus became a global pandemic in early 2020, knowing that they may have antiviral properties, he started screening his old collection, first in cells with collaborators from Sorrento Therapeutics and The University of Texas Medical Branch, and later, after seeing promising results, working with Scripps Research immunologist John Teijaro, PhD, who conducted rodent studies.
One compound stood out. Dubbed simply "No. 11," it differs from the commercial tapeworm medicines in key ways, including its ability to pass beyond the gut and be absorbed into the bloodstream -- and without the worrisome toxicity.
"Niclosamide is basically digestive-track restricted, and that makes sense, because that's where parasites reside," Janda says. "For that reason, simple drug repurposing for a COVID treatment would be counterintuitive, as you want something that is readily bioavailable, yet does not possess the systemic toxicity that niclosamide has."
About 80 percent of salicylanilide 11 passed into the bloodstream, compared to about 10 percent of the antiparasitic drug niclosamide, which has recently entered clinical trials as a COVID-19 treatment, Janda says.
The experiments showed that of the many modified salicylanilides he had built in his laboratory, No. 11 affected pandemic coronavirus infections in two ways. First, it interfered with how the virus deposited its genetic material into infected cells, a process called endocytosis. Endocytosis requires the virus to form a lipid-based packet around viral genes. The packet enters the infected cell and dissolves, so the infected cell's protein-building machinery can read it and churn out new viral copies. No. 11 appears to prevent the packet's dissolution.
"The compound's antiviral mechanism is the key," Janda says. "It blocks the viral material from getting out of the endosome, and it just gets degraded. This process does not allow new viral particles to be made as readily."
Importantly, because it acts inside cells rather than on viral spikes, questions about whether it would work in new variants like Delta and Lambda aren't a concern, he adds.
"This mechanism is not dependent on the virus spike protein, so these new variants coming up aren't going to relegate us to finding new molecules as is the case with vaccines or antibodies," Janda says.
In addition, No. 11 helped quiet potentially toxic inflammation in the research animals, Janda says, which could be important for treating acute respiratory distress associated with life-threatening COVID infections. It reduced levels of interleukin 6, a signaling protein which is a key contributor of inflammation typically found in advanced stages of COVID-19.
Better medications against COVID-19 are urgently needed, as highly infectious new variants drive renewed surges of illness and death globally. But Janda says salicylanilide No. 11 was created long before the pandemic.
After fighting an unpleasant bacterial infection called Clostridioides difficile about 10 years ago,he saw a clear need for better treatment options. Multi-drug-resistant strains of C. difficile have become a major cause of drug-resistant diarrheal disease outbreaks in health care institutions globally, and among people using antibiotics. As director of the Worm Institute, which focused on parasitic infections, Janda was very familiar with salicylanilides, and knew of their antimicrobial properties. His laboratory created a "library" of modified salicylanilides several of which showed strong efficacy against C. difficile, and the collection was subsequently licensed by pharmaceutical firm Sorrento Therapeutics. Among them was salicylanilide 11.
"Salicylanilide 11 actually was placed on the back burner in my laboratory against C. difficile because it's not as gut-restricted as we would like it to be," Janda says. "But salicylanilide 11 has got a lot of really positive things going for it as a potential therapeutic for COVID."
Rest at link. Bolded and underlined emphasis is mine. Apparently this is previously licensed and should be cheap.
Remdesivir is a cheap NAD+ copy, which isn't that effective compared to natural NAD+ precursers like Niacin. Average regeneration duration with high dose Nicotinic Acid (Niacin) is 1,3 days and approx 10 days in control group. Check out the work of Dimitry Kats. @nia3in on Twitter. https://twitter.com/nia3in
Posted 09 August 2021 - 03:08 AM
Re Niclosamide at Hebbeh #3034.
The late ice9 suggested niclosamide.
https://twitter.com/...854867668230144
ce9: For post-exposure prophylaxis, bromhexine+nitazoxanide+ivermectin is a simple and inexpensive combination. HCQ can be used instead of nitazoxanide if desired, though nitazoxanide is likely more effective given it also works in monotherapy....
Interlocutor: Where can we get nitazoxanide
Ice9: Offshore pharmacies mostly. eBay also has niclosamide, which is just as good as far as I can tell (possibly better), but does not have direct RCT evidence. Same mechanisms, higher potency relative to clinically attained concentrations.
Available on ebay: https://www.ebay.com...FMAAOSwqORg96-c
Posted 09 August 2021 - 01:20 PM
Article on the motivation for the EGCG trial - LINK
HIP, what is your pharmacokinetic opinion about EGCG given the H1N1 trial they mention in this article and the high binding affinity it has for covid(page 7 in this study)?
Luckily Curcumin helps with its absorption and is number 2 on the binding list.
Edited by Gal220, 09 August 2021 - 01:22 PM.
Posted 09 August 2021 - 01:47 PM
I wonder to what extent that Quercetin/Curcumin/EGCG have similar MOAs and therefore might not give you a tremendous amount of synergy when used in combination.
There tends to be a lot of overlap in these flavanol/flavanoids in how they work. Normally, you get the most synergy when combining different therapeutics that have different MOAs, provided of course that the MOAs don't actually conflict.
Edited by Daniel Cooper, 09 August 2021 - 01:50 PM.
Posted 10 August 2021 - 02:15 PM
"Presumably Patterson has found success treating several before posting the protocol"
He said that he had, I believe.
In line with his protocol, you can connect some dots.
Patterson's view is that reducing C16+ (S1 / spike protein presenting) monocytes will control COVID severity, long COVID, and vaccine symptoms.
Patterson's pharmaceutical of choice is difficult to get and comes with a black box warning, though Patterson states that it is safe.
What else reliably triggers monocyte apoptosis?
Synthetic and perhaps occassional nicotine.
* Note: this is not a recommendation to smoke (or any). If you decide to try nicotine, get it in lozenge form and consider spacing out the treatment to minimize addiction.
This does not kill the virus. Theoretically, this maximally reduces harmful cardiovascular and inflammatory effects from S1 presenting monocytes that will form from any source of spike protein. These monocytes will pool with ever more exposure.
https://www.webmd.co...en-for-covid-19
https://harmreductio...954-020-00437-5
Note that apoptosis is the desired effect, not just inflammation reduction as we might see in other (still positive) interventions, as these monocytes last out to 15 months.
C16+ monocytes are (also) antiinflammatory, but we don't want to bias toward them
https://pubmed.ncbi....h.gov/27771381/
https://www.research...dent_Mechanisms
IMO, if one isn't going to vaccinate then keeping S1 presenting c16+ monocyte pool to a minimum could be the best overall prophylaxis, especially if one is continuously exposed to spike protein by being around vaxed and COVID carrying people. Even if you are vaxed, the same philosophy might apply.
Edited by Ames, 10 August 2021 - 02:19 PM.
Posted 10 August 2021 - 04:30 PM
I was intrigued by the smokers paradox first noticed in China early on. About 50% of the adult males smoke in China, but hospital COVID & ICU census was much lower. "Where were all the smokers"?
In looking into nicotine, I saw it was a "lipid soluble alkaloid", which caught my attention as the chloroquine drugs are also lipid soluble alkaloids and one mechanism of action was the alkalizing of lysosomes where the virus replicates.
In looking into other lipid soluble alkaloids, I found there actually wen't a lot of options. Caffeine, nicotine, quinine/chloroquine/HCQ and theobromine in cocoa/chocolate.
I switched my evening tipple from red wine to gin & tonic for some low dose quinine & started consuming chocolate every evening. A large black coffee after lunch for caffeine, & I've even got some nicotine gum in my medicine chest.
Might this slow the lightning replication rate being reported with Delta? Don't know, but medicine never tasted so good. An easy protocol to follow.
Edited by Dorian Grey, 10 August 2021 - 04:33 PM.
Posted 11 August 2021 - 12:19 AM
According to Dimitri Kats, nicotine is oxidized to nicotinic acid (niacin) during combustion and this may explain the smoker paradox re covid. He is promoting niacin as a therapeutic. He says the flush is necessary, so it has to be niacin.
I am not sure what to make of his theory, but nicotinic acid is anti-inflammatory for monocytes and macrophages.
Posted 12 August 2021 - 04:15 PM
Drug that reduces the cytokine storm rescues 90% of serious COVID patients. Phase 2 trial in Israel.
Yet another option that will be ignored/banned by the FDA, CDC, WHO, etc, and other "health" bureaucrats.
Hopefully FLCCC is monitoring the progress of this therapeutic. That way people who suffer more significantly from COVID (or other cytokine-storm related respiratory illnesses), will have options.
Posted 12 August 2021 - 04:36 PM
Drug that reduces the cytokine storm rescues 90% of serious COVID patients. Phase 2 trial in Israel.
Yet another option that will be ignored/banned by the FDA, CDC, WHO, etc, and other "health" bureaucrats.
Hopefully FLCCC is monitoring the progress of this therapeutic. That way people who suffer more significantly from COVID (or other cytokine-storm related respiratory illnesses), will have options.
This one has a chance of approval. It consists of exosomes enriched for CD24. Administered as a aerosol in saline. (https://clinicaltria...how/NCT04747574). As a biologic, it will be fairly expensive and its availability readily controlled by gatekeepers. Also, it targets the cytokine storm. So it will not be an early treatment, but might be an improvement over glucocorticoids. So the regulatory agencies might like it.
Edited by DanCG, 12 August 2021 - 04:41 PM.
Posted 12 August 2021 - 05:58 PM
"California is reporting 141.1 new coronavirus cases for every 100,000 residents over the last seven days — a rate half that of Texas, 297.8; and less than one-fourth that of Florida’s rate of 653.8, according to data from the U.S. Centers for Disease Control and Prevention. California’s rate is also less than the national average of 232.1."
"Experts say California’s better-than-average vaccination rates and newly implemented mandatory mask policies in parts of the state have helped prevent a more grim situation."
"Out of 117 people admitted to Los Angeles County’s public hospitals primarily for COVID-19 between June 15 and Aug. 5, 112 were not fully vaccinated and only five were fully vaccinated, according to Dr. Christina Ghaly, the county’s director of health services."
Posted 12 August 2021 - 09:40 PM
is it possible to reverse previous vaccinations by taking them twice or something? I wish I never had any vaccines who knows if it affected me negatively while I was a child or not.
Edited by kurdishfella, 12 August 2021 - 09:41 PM.
Posted 12 August 2021 - 10:04 PM
Re: post #3047
Yes and no. Depending on what you mean by "reverse previous vaccinations". Reference here and here.
Ignore the above. Actually, the only way to reverse a vaccination is by means of another shot. The shot would be delivered via a .44 magnum hollowpoint (propelled from what was once the most powerful handgun in the world, right Harry?) directed toward the pre-frontal lobes (not the earlobes, if you know what I mean).
Posted 13 August 2021 - 12:41 AM
This topic is getting too large. -- Topics with too may posts make it difficult for new entrants to catch up. There are usually many sub-topics that could more usefully be pursued in a focused thread. Some of the most pertinent posts may be hard to locate. Most importantly though, excessively long topics are not great for site performance, server load and loading times.
This topic will be closed -- This is an advance notice. The lock may not happen for days or weeks, and might depend on new topics emerging as described below. Like all other discussions on LongeCity (dating back many years) this thread will remain freely and publicly accessible indefinitely.
You can help start a new topic that picks up the discussion. Before you do that, it would be great if you could consider the following guidelines:
Make sure you update your subscription to the new topic(s). You don't have to cancel the existing subscription, but obviously they will no longer be useful in alerting you after the topic has been closed.
Posted 13 August 2021 - 02:54 AM
Drug that reduces the cytokine storm rescues 90% of serious COVID patients. Phase 2 trial in Israel.
Yet another option that will be ignored/banned by the FDA, CDC, WHO, etc, and other "health" bureaucrats.
Hopefully FLCCC is monitoring the progress of this therapeutic. That way people who suffer more significantly from COVID (or other cytokine-storm related respiratory illnesses), will have options.
Posted 13 August 2021 - 03:29 AM
FLCCC update video regarding more agressive treatment protocol. Also that in spite of following the prevention protocol, Dr. Kory got covid. See around 12 minutes in.
https://odysee.com/@...—8-11-21—dr.:1?
Posted 13 August 2021 - 03:26 PM
The increased dosing & breakthroughs with the ivermectin prophylaxis protocol are a bit concerning to me. I stumbled across Dr Zelenko's hydroxychloroquine prophylaxis protocol the other day, & was quite impressed with the minimalist simplicity.
https://vladimirzele...laxis-protocol/
"Elemental Zinc 25mg once a day Vitamin D3 5000iu 1 time a day Hydroxychloroquine (HCQ) 200mg 1 time a day for 5 days, then 1 time a week until a safe and efficacious vaccine becomes available"
Oh wow! After five days loading, just one 200mg dose HCQ per week? This struck me as a safe, easy & wise addition to IVM prophylaxis. Started my 5 day loading on Wednesday, and all is going well. The 200mg once per day loading is half the normal daily therapeutic dose, so I had no noticeable side effects.
I recall Dr Marik saying the reason he didn't like HCQ is that red blood cells tend to take up nearly all of the med during the first few days, delaying therapeutic plasma & tissue levels to a point a bit late in the game for effectiveness with COVID. Would pre-loading & maintenance dosing prophylaxis also allow for a more rapid response to therapeutic dosing in a breakthrough illness? Makes sense to me.
I've always thought HCQ got a bad rap, with most all trials starting therapy very late in the game. Still, considerable and compelling evidence for benefit.
I'm betting being pre-loaded with prophylactic dosing will give me a head start on achieving therapeutic blood & tissue levels if I need to up the ante for a Delta breakthrough. I also hope to avoid the ever increasing doses & frequency of the FLCCC IVM prophylaxis protocol. 12mg IVM with a fatty meal once or twice a month is about all I'm comfortable with, & adding HCQ prophylaxis may allow me to have the best of both worlds.
Posted 13 August 2021 - 11:00 PM
The increased dosing & breakthroughs with the ivermectin prophylaxis protocol are a bit concerning to me. I stumbled across Dr Zelenko's hydroxychloroquine prophylaxis protocol the other day, & was quite impressed with the minimalist simplicity.
Parts of the early outpatient does look amateurish to me - Link
No NAC or Glutathione, limited vitamin C, no H202 inhalation, blood cleanser, beta glucans, or other anti-virals EGCG, Cucumin, Licorice etc.
Posted 15 August 2021 - 09:04 PM
Here's an interesting concept: https://defyccc.com/...ainst-covid-19/
Proposed Protocol for Self-Immunization against COVID-19
This appears similar to the Zelenko prophylaxis protocol I posted above. Low dose maintenance HCQ to protect the lungs. Knock out any breakthrough infection with IVM and/or increased HCQ, & you obtain natural post-infection immunity with relative safety.
This may work with post vaccination breakthrough cases (and perhaps ADE complication), as well as the un-vaccinated.
Posted 18 August 2021 - 04:15 AM
I will miss the protection thread when it is closed. I think protection from Covid-19 is a pretty good topic for a longevity board, and I liked that alternative theories and vaccine debates had their own threads.
Here is a most highly recommended source worth posting as twilight looms.
This is like the Covid-19 subreddit in focusing on scientific reports, but led by one person and more evaluative and more heterodox in what it considers. It is less chaotic and more reader-friendly than many twitter threads. It is what an ideal protection thread here on longevity here might be if there were more energy and expertise available. The author seems not to be pseudoscientific in either direction (authoritarian orthodoxy, gullible heterodoxy). Most recent topics, just over two days:
Borody preprint on ivermectin, doxycline, zinc, C, and D
Summary of carrageenan nasal-spray RCT results
Preprint on saline nasal irrigation, povidone nasal irrigation
Ivermectin in Uttar Pradesh
DeSantis pro early treatment
Together Ivermectin trial
Nebulized HCQ
Nigella sativa preventive, cardioprotective? Upcoming RCTs, India news reports
Budesonide, HCQ, Ivermectin relative risk
Criticism of Together trial protocol
Enovid nasal spray
Underpowered Pyramax (pyronaridine-artesunate) trial in Korea
Etc., etc., etc.
I also picked up some nifty links from Covid19Crusher.
Do it yourself meta-analysis!
“Living meta-analysis and evidence synthesis of therapies for COVID19”
Try it. http://metaevidence....2&selAnalysis=3
Bias assessments for each of many Covid-19 trials, with red, yellow, and green ratings, also linked to details that justify the summary rating. https://covid-nma.co..._data/index.php
Cited at longecity numerous times, but still good to remind: https://c19early.com/
Edited by bladedmind, 18 August 2021 - 04:20 AM.
Posted 18 August 2021 - 04:39 AM
Israel observational study of people’s everyday drugs and Covid19 outcome.
Results:Conclusions:Medications associated with most significantly reduced odds for COVID-19 hospitalization include: ubiquinone (OR=0.185, 95% CI [0.058 to 0.458], p<0.001), ezetimibe (OR=0.488, 95% CI [0.377 to 0.622], p<0.001), rosuvastatin (OR=0.673, 95% CI [0.596 to 0.758], p<0.001), flecainide (OR=0.301, 95% CI [0.118 to 0.641], p<0.001), and vitamin D (OR=0.869, 95% CI [0.792 to 0.954], p<0.003). Remarkably, acquisition of artificial tears, eye care wipes, and several ophthalmological products were also associated with decreased risk for hospitalization.
Ubiquinone, ezetimibe, and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings point to a promising protective effect which should be further investigated in controlled, prospective studies.
Just a reminder, simple things like handwashing, saline nasal irrigation, and OTC cetylpyridinium mouthwash gargles probably help prevent Covid19. I speculate that dry eyes, that some of us suffer from, are an entry opportunity for Covid19. My dry eyes have improved somewhat with ivermectin because it kills the demodex beasts clogging up eyellid glands and eyelash follicles.
Posted 18 August 2021 - 01:20 PM
Before it is closed, there is a partial summary below which might be useful for reference (google translate may or may not be needed):
https://forums.huare...topicid=2546619
Summary of Using Supplements for Mild COVID-19 Cases
Posted 18 August 2021 - 02:33 PM
Needs references on my 3057?
A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro
Clinical treatment of ocular Demodex folliculorum by systemic ivermectin
Posted 18 August 2021 - 03:52 PM
The increased dosing & breakthroughs with the ivermectin prophylaxis protocol are a bit concerning to me. I stumbled across Dr Zelenko's hydroxychloroquine prophylaxis protocol the other day, & was quite impressed with the minimalist simplicity.
https://vladimirzele...laxis-protocol/
"Elemental Zinc 25mg once a day Vitamin D3 5000iu 1 time a day Hydroxychloroquine (HCQ) 200mg 1 time a day for 5 days, then 1 time a week until a safe and efficacious vaccine becomes available"
Oh wow! After five days loading, just one 200mg dose HCQ per week? This struck me as a safe, easy & wise addition to IVM prophylaxis. Started my 5 day loading on Wednesday, and all is going well. The 200mg once per day loading is half the normal daily therapeutic dose, so I had no noticeable side effects.
I recall Dr Marik saying the reason he didn't like HCQ is that red blood cells tend to take up nearly all of the med during the first few days, delaying therapeutic plasma & tissue levels to a point a bit late in the game for effectiveness with COVID. Would pre-loading & maintenance dosing prophylaxis also allow for a more rapid response to therapeutic dosing in a breakthrough illness? Makes sense to me.
I've always thought HCQ got a bad rap, with most all trials starting therapy very late in the game. Still, considerable and compelling evidence for benefit.
I'm betting being pre-loaded with prophylactic dosing will give me a head start on achieving therapeutic blood & tissue levels if I need to up the ante for a Delta breakthrough. I also hope to avoid the ever increasing doses & frequency of the FLCCC IVM prophylaxis protocol. 12mg IVM with a fatty meal once or twice a month is about all I'm comfortable with, & adding HCQ prophylaxis may allow me to have the best of both worlds.
DO we know yet if lysine is useful as a prohylactic. there is this guy Bo on youtube who reported many of the people he prescribed his Lysine protocol have had very fast recoveries..
Round Table Discussion →
Risks & Survival →
COVID →
Polio vaccine booster more effective than COVID vaccine (if you had Oral Polio Vaccine as a child).Started by smithx , 06 Aug 2024 coronavirus |
|
|
||
Round Table Discussion →
Risks & Survival →
COVID →
ArtemisininStarted by joesixpack , 05 Jun 2024 coronavirus |
|
|
||
Round Table Discussion →
Risks & Survival →
COVID →
COVID-19 pandemic: the aftermathStarted by Galaxyshock , 14 Mar 2024 coronavirus |
|
|
||
Round Table Discussion →
Risks & Survival →
COVID →
Antidepressant prescribing for youths surged during COVIDStarted by Daniel Cooper , 28 Feb 2024 coronavirus |
|
|
||
Science & Health →
Supplements →
Senolytics →
Immune Peptide Bioregulators Effect on Senescent CellsStarted by Automail , 22 Dec 2023 peptides, immunity, joints and 2 more... |
|
|
0 members, 28 guests, 0 anonymous users